Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07717931
PHASE4

Vitamin D Therapy to Prevent Recurrent Preeclampsia in High-Risk Pregnancies

Sponsor: CMH Multan Institute of Medical Sciences

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to determine whether vitamin D supplementation can reduce the recurrence of preeclampsia in pregnant women with a previous history of preeclampsia. The main questions the study aims to answer are: \- Does daily vitamin D supplementation reduce the recurrence of preeclampsia compared with a placebo? Researchers will randomly assign 146 eligible pregnant women to receive either vitamin D supplements or a placebo. The two groups will be compared to determine whether vitamin D lowers the risk of recurrent preeclampsia. Participants will: * Be randomly assigned to receive either 4000 IU oral vitamin D once daily or a matching placebo. * Take the assigned study medication daily until 36 weeks of gestation. * Attend follow-up visits every 2 weeks for blood pressure measurement and clinical assessment. * Have serum vitamin D levels measured every 4 weeks to monitor for vitamin D toxicity. * Undergo urine testing for protein if blood pressure is elevated to assess for preeclampsia. The results of this study will help determine whether vitamin D supplementation is an effective and safe strategy for preventing recurrent preeclampsia in women at high risk.

Official title: Preventing Preeclampsia Recurrence in High-Risk Pregnancies Using Vitamin D Therapy: A Randomized Controlled Trial

Key Details

Gender

FEMALE

Age Range

20 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

146

Start Date

2025-08-01

Completion Date

2026-01-30

Last Updated

2026-07-21

Healthy Volunteers

No

Conditions

Interventions

DRUG

Vitamin D (Cholecalciferol )

Vitamin D 4000 IU will be administered orally once daily from enrollment until 36 weeks of gestation. They will attend follow-up visits every 2 weeks for blood pressure monitoring and clinical assessment, with serum vitamin D levels measured every 4 weeks.

DRUG

Placebo

A matching placebo with the same taste, color, and consistency as vitamin D will be administered orally once daily from enrollment until 36 weeks of gestation for comparison with vitamin D supplementation.

Locations (1)

CMH Multan Institute of Medical Sciences

Multan, Punjab Province, Pakistan